Gepants vs Anti-CGRP Monoclonal Antibodies for Migraine Prevention
Anti-CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) have stronger evidence and receive "strong for" recommendations for both episodic and chronic migraine prevention, while gepants (atogepant, rimegepant) receive weaker recommendations with atogepant rated "weak for" and rimegepant "neither for nor against" for episodic migraine. 1
Evidence Strength and Guideline Recommendations
The 2024 VA/DoD guidelines upgraded anti-CGRP mAbs to "strong for" recommendations based on network meta-analysis of 6,979 patients from 13 RCTs, demonstrating consistent reductions in monthly migraine days and acute medication use for both episodic and chronic migraine 1. In contrast, gepants entered guidelines more recently with weaker evidence: atogepant showed statistically significant reductions across 2,466 patients in 3 RCTs, while rimegepant's 0.8-day reduction in monthly migraine days was deemed not clinically significant by guideline authors 1.
The American Headache Society position statement (2024) considers both classes as first-line options, though this represents expert opinion rather than differential grading 2.
Efficacy Comparison
Episodic Migraine
- Anti-CGRP mAbs: Monthly fremanezumab 225 mg showed the greatest reduction in migraine days (SMD -0.49) and highest 50% response rate (RR 2.98) in network meta-analysis 3
- Gepants: Atogepant 60 mg demonstrated effectiveness with fewer side effects, but overall smaller effect sizes 3
- Real-world data shows atogepant achieves approximately 30% response rate (≥50% reduction in migraine days) at 3 months in treatment-refractory patients 4
Chronic Migraine
Anti-CGRP mAbs maintain strong efficacy in chronic migraine with "strong for" recommendations 1. Gepants have limited data for chronic migraine prevention.
Indications
Anti-CGRP mAbs:
- FDA-approved for both episodic and chronic migraine prevention
- Can be used as first-line therapy
- Particularly effective when ≥4 migraine days/month or ≥2 days with significant disability despite acute treatment 1
Gepants:
- Atogepant: FDA-approved for episodic migraine prevention
- Rimegepant: Approved for both acute treatment and prevention of episodic migraine
- May be considered after mAb failure, though response decreases with each prior failed anti-CGRP therapy 4
Dosing
Anti-CGRP mAbs (all subcutaneous or IV):
- Erenumab: 70 mg or 140 mg monthly SC
- Fremanezumab: 225 mg monthly or 675 mg quarterly SC
- Galcanezumab: 240 mg loading dose, then 120 mg monthly SC
- Eptinezumab: 100 mg or 300 mg quarterly IV
Gepants (oral):
- Atogepant: 60 mg daily (10 mg, 30 mg, or 60 mg options)
- Rimegepant: 75 mg every other day for prevention
Side Effects and Tolerability
Anti-CGRP mAbs
- Most common: Injection site reactions, constipation, nasopharyngitis
- Serious concern: Erenumab carries postmarketing warning for development or worsening of hypertension—monitor blood pressure 1
- Galcanezumab 240 mg showed highest odds of treatment-emergent adverse events (OR 1.63) 5
- Eptinezumab associated with lowest odds of treatment-emergent adverse events among mAbs 5
- No significant differences in serious adverse events versus placebo 5
Gepants
- Most common: Constipation (30%), nausea (25%) 4
- Atogepant 120 mg showed highest odds of treatment-emergent adverse events among all CGRP-targeting therapies (OR 2.22) 5
- In real-world use, 52.5% reported adverse events, with 26.2% discontinuing by 3 months (28.8% due to intolerance) 4
- Generally well-tolerated with rare serious adverse events 5
Key Clinical Considerations
When to choose anti-CGRP mAbs:
- First-line therapy for episodic or chronic migraine
- Patient preference for monthly/quarterly dosing
- Chronic migraine (stronger evidence base)
- Adherence concerns with daily oral medication
When to consider gepants:
- Patient preference for oral medication
- After mAb failure (though response rates decrease: RR 0.79 per failed mAb) 4
- Episodic migraine with milder disease burden
- Patients who can tolerate daily medication
Critical pitfall: Each failed anti-CGRP therapy (whether mAb or gepant) reduces likelihood of response to subsequent CGRP-targeting treatments 4. Real-world data shows 39.7% response rate after one failed mAb, decreasing with multiple failures 4.
Switching strategy: Approximately one-third of patients may benefit from switching from one anti-CGRP mAb to another 6. Atogepant after mAb failure achieves 29.7% response rate at 3 months, but this decreases significantly with multiple prior mAb failures 4.
Cardiovascular monitoring: Monitor blood pressure with erenumab due to postmarketing hypertension risk 1. Limited data exists for patients with recent stroke, MI, or significant vascular disease—use caution in these populations 7.
Treatment persistence: Real-world atogepant persistence at 6 months is 61%, with most discontinuations due to inefficacy (65.1%) rather than tolerability (28.8%) 4.